Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics
Alberta HEART
1 other identifier
observational
700
1 country
2
Brief Summary
The objectives of this study are: 1) to design new diagnostic criteria used to accurately define heart failure with preserved ejection fraction (HFpEF); 2) to better define the risk factors associated with HFpEF; 3) to elucidate the clinical, cellular and molecular mechanisms involved with the development and progression of HFpEF; 4) to design and test new therapeutic strategies for patients with HFpEF.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2009
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2009
CompletedFirst Submitted
Initial submission to the registry
January 21, 2014
CompletedFirst Posted
Study publicly available on registry
February 3, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
May 2, 2022
CompletedMay 3, 2022
May 1, 2022
6.7 years
January 21, 2014
May 2, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Percent of patients meeting new diagnostic criteria for HFpEF
Up to 5 years
Eligibility Criteria
Residents of Alberta, Canada with heart failure or at risk for developing heart failure
You may qualify if:
- Group 1 No clinically overt heart failure
- Group 2 Known coronary artery disease
- Group 3 Known heart failure with preserved ejection fraction
- Group 4 Known heart failure with reduced ejection fraction
- Group 5 Healthy age-matched controls
You may not qualify if:
- Age \<18 years
- Known malignancy with expected survival \<1 year
- Pregnant or recent pregnancy \<6 months
- Recent event (\<2 weeks since Acute Coronary Syndrome, Heart failure or other admission
- Severe mitral or aortic stenosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
University of Calgary
Calgary, Alberta, T2N 4N1, Canada
University of Alberta
Edmonton, Alberta, T6G 2E1, Canada
Related Publications (2)
Zordoky BN, Sung MM, Ezekowitz J, Mandal R, Han B, Bjorndahl TC, Bouatra S, Anderson T, Oudit GY, Wishart DS, Dyck JR; Alberta HEART. Metabolomic fingerprint of heart failure with preserved ejection fraction. PLoS One. 2015 May 26;10(5):e0124844. doi: 10.1371/journal.pone.0124844. eCollection 2015.
PMID: 26010610DERIVEDEzekowitz JA, Becher H, Belenkie I, Clark AM, Duff HJ, Friedrich MG, Haykowsky MJ, Howlett JG, Kassiri Z, Kaul P, Kim DH, Knudtson ML, Light PE, Lopaschuk GD, McAlister FA, Noga ML, Oudit GY, Paterson DI, Quan H, Schulz R, Thompson RB, Weeks SG, Anderson TJ, Dyck JR. The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. BMC Cardiovasc Disord. 2014 Jul 25;14:91. doi: 10.1186/1471-2261-14-91.
PMID: 25063541DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Jason Dyck, PhD
University of Alberta
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor, University of Alberta; Director, Heart Function Clinic- Mazankowski Alberta Heart Institute
Study Record Dates
First Submitted
January 21, 2014
First Posted
February 3, 2014
Study Start
April 1, 2009
Primary Completion
December 1, 2015
Study Completion
May 2, 2022
Last Updated
May 3, 2022
Record last verified: 2022-05